MedTrace Logo

Recommendations for the Treatment of Children With Burkitt's Lymphoma

NCT04425421 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 1000

Last updated 2026-03-02

No results posted yet for this study

Summary

This is the 4th LMB study by the French African Pediatric Oncology Group (GFAOP). The study hopes to be able to evaluate children earlier with stage I and II disease and to evaluate treatment response earlier so that the units can decide if a change in treatment is necessary, it is also hoped to provide an intensification of treatment for the stage IV disease.

Conditions

  • Burkitt Lymphoma

Interventions

OTHER

OBSERVATIONAL

OBSERVAITON OF THE CAPACITY OF THE GROUP TO TREAT ACCORDING TO THE PROTOCOLE AND LOOK AT OUTCOME FOR STAGE I AND II DISEASE

Sponsors & Collaborators

  • French Africa Pediatric Oncology Group

    lead OTHER

Eligibility

Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-11-01
Primary Completion
2028-12-31
Completion
2030-12-31

Countries

  • Burkina Faso
  • Côte d’Ivoire
  • Democratic Republic of the Congo
  • Madagascar
  • Mali
  • Senegal

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04425421 on ClinicalTrials.gov